The use of an anti-VEGF antibody in combination with chemotherapy may enhance the efficacy of chemotherapy toward retinoblastoma [64, 65], despite a distinct toxicity profile in use for clinical trials. This evidence concerns the gene VEGFA and retinoblastoma.